HK1218393A1 - Composition for treating a pulmonary hypertension - Google Patents

Composition for treating a pulmonary hypertension Download PDF

Info

Publication number
HK1218393A1
HK1218393A1 HK16106422.7A HK16106422A HK1218393A1 HK 1218393 A1 HK1218393 A1 HK 1218393A1 HK 16106422 A HK16106422 A HK 16106422A HK 1218393 A1 HK1218393 A1 HK 1218393A1
Authority
HK
Hong Kong
Prior art keywords
ambrisentan
subject
baseline
composition
pah
Prior art date
Application number
HK16106422.7A
Other languages
English (en)
Chinese (zh)
Inventor
Michael J. Gerber
Christopher Dufton
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1218393(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of HK1218393A1 publication Critical patent/HK1218393A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16106422.7A 2006-12-12 2016-06-06 Composition for treating a pulmonary hypertension HK1218393A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86966706P 2006-12-12 2006-12-12
US869667P 2006-12-12

Publications (1)

Publication Number Publication Date
HK1218393A1 true HK1218393A1 (en) 2017-02-17

Family

ID=39092031

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106422.7A HK1218393A1 (en) 2006-12-12 2016-06-06 Composition for treating a pulmonary hypertension

Country Status (15)

Country Link
US (7) US20080139593A1 (enExample)
EP (2) EP2952193A1 (enExample)
JP (1) JP2010512414A (enExample)
AU (1) AU2007333115B2 (enExample)
CA (1) CA2669536C (enExample)
CY (1) CY2016017I2 (enExample)
DK (1) DK2101777T3 (enExample)
ES (1) ES2544724T3 (enExample)
HK (1) HK1218393A1 (enExample)
HU (2) HUE025355T2 (enExample)
LU (1) LU93081I2 (enExample)
PL (1) PL2101777T3 (enExample)
PT (1) PT2101777E (enExample)
SI (1) SI2101777T1 (enExample)
WO (1) WO2008073928A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2544724T3 (es) 2006-12-12 2015-09-03 Gilead Sciences, Inc. Composición para tratar una hipertensión pulmonar
CA2693400A1 (en) * 2007-07-11 2009-01-15 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
CA2695259C (en) 2007-07-31 2016-05-24 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
WO2010062640A1 (en) * 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications
KR20130088834A (ko) * 2010-06-30 2013-08-08 길리애드 사이언시즈, 인코포레이티드 폐 고혈압의 치료를 위한 ａ２ｂ 아데노신 수용체 길항제의 용도
ES2627944T3 (es) 2010-10-15 2017-08-01 Gilead Sciences, Inc. Composiciones y métodos de tratamiento de hipertensión pulmonar
EP2741777B1 (en) * 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US20130225595A1 (en) * 2012-02-29 2013-08-29 Gilead Sciences, Inc. Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis
US20130224306A1 (en) * 2012-02-29 2013-08-29 Gilead Sciences, Inc. Method for treating a pulmonary hypertension condition without companion diagnosis
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2015193889A1 (en) * 2014-06-18 2015-12-23 Sonivie Ltd. Method for treating secondary pulmonary hypertension
US10576083B2 (en) * 2015-08-13 2020-03-03 Cipla (UK) Limited Method of treating pulmonary arterial hypertension
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
SG11202000893QA (en) * 2017-08-30 2020-02-27 Bellerophon Pulse Tech Llc Use of inhaled nitric oxide for the treatment of pulmonary hypertension associated with lung disease
EA202091286A1 (ru) * 2017-12-28 2020-11-05 Беллерофон Пульс Текнолоджис Ллс Применение вдыхаемого оксида азота (ii) и кислорода для лечения легочной гипертензии
EP3965767A1 (en) * 2019-05-06 2022-03-16 Actelion Pharmaceuticals Ltd Methods for treating sarcoidosis-associated pulmonary hypertension
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
RU2729033C1 (ru) * 2020-02-03 2020-08-03 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ прогнозирования эффективности длительной специфической терапии у пациентов с идиопатической легочной гипертензией и неоперабельной хронической тромбоэмболической легочной гипертензией
EP4142731A1 (en) * 2020-04-28 2023-03-08 Noorik Biopharmaceuticals AG Treatment of pulmonary complications of coronavirus infections
EP3906928A1 (en) * 2020-05-06 2021-11-10 Noorik Biopharmaceuticals AG Treatment of pulmonary complications of coronavirus
CN114324900A (zh) * 2021-12-03 2022-04-12 上海市肺科医院 一种促卵泡激素的应用
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
AU2024207876A1 (en) * 2023-01-09 2025-07-31 Scpharmaceuticals Inc. Methods of treatment using loop diuretics

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4325525A (en) 1980-11-13 1982-04-20 General Motors Corporation Mounting member
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DK1174431T3 (da) 1997-11-12 2012-08-20 Bayer Pharma AG 2-phenyl-substitueret imidazo triazinon som phoshodiesterase-inhibitorer
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
WO2006007213A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
TW200621261A (en) 2004-08-26 2006-07-01 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
WO2006081289A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
SI2013208T1 (sl) * 2006-04-21 2011-09-30 Pfizer Prod Inc Piridin(3,4-b)pirazinoni
EP2091539A1 (en) * 2006-12-12 2009-08-26 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
ES2544724T3 (es) * 2006-12-12 2015-09-03 Gilead Sciences, Inc. Composición para tratar una hipertensión pulmonar
CA2695259C (en) 2007-07-31 2016-05-24 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
WO2010062640A1 (en) 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications
ES2627944T3 (es) 2010-10-15 2017-08-01 Gilead Sciences, Inc. Composiciones y métodos de tratamiento de hipertensión pulmonar

Also Published As

Publication number Publication date
US20150224100A1 (en) 2015-08-13
US8377933B2 (en) 2013-02-19
PL2101777T3 (pl) 2015-10-30
LU93081I2 (fr) 2016-07-20
CY2016017I1 (el) 2016-10-05
JP2010512414A (ja) 2010-04-22
EP2101777B1 (en) 2015-05-20
US9474752B2 (en) 2016-10-25
AU2007333115B2 (en) 2013-01-10
ES2544724T3 (es) 2015-09-03
HUS1600027I1 (hu) 2016-06-28
US20080139593A1 (en) 2008-06-12
US20110245253A1 (en) 2011-10-06
WO2008073928A1 (en) 2008-06-19
EP2101777A1 (en) 2009-09-23
CA2669536C (en) 2016-05-31
US20130116257A1 (en) 2013-05-09
US20140296244A1 (en) 2014-10-02
US9993475B2 (en) 2018-06-12
US9504685B2 (en) 2016-11-29
HUE025355T2 (en) 2016-02-29
EP2952193A1 (en) 2015-12-09
CY2016017I2 (el) 2016-10-05
CA2669536A1 (en) 2008-06-19
US20100152217A1 (en) 2010-06-17
AU2007333115A1 (en) 2008-06-19
SI2101777T1 (sl) 2015-08-31
US20170136016A1 (en) 2017-05-18
PT2101777E (pt) 2015-09-18
DK2101777T3 (en) 2015-08-17

Similar Documents

Publication Publication Date Title
HK1218393A1 (en) Composition for treating a pulmonary hypertension
TWI542580B (zh) 治療肺高血壓的組合物及方法
EP2531187B1 (en) sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS
US20120004188A1 (en) Use of ranolazine for treating pulmonary hypertension
WO2010062640A1 (en) Methods for treating idiopathic pulmonary fibrosis and associated complications
JP2009520806A (ja) ＰＤＥ−５阻害薬と５−α還元酵素阻害薬の医薬組合せ
EP1254120B1 (en) Use of pyrimidine endothelin antagonists in companion animals
TWI900606B (zh) 用於治療內皮素相關疾病之齊泊騰坦和達格列淨的組合
AU2021382896A1 (en) Methods of using 4-amino-n-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide for the treatment of tumors
KR20250099240A (ko) 간질성 폐 질환 치료를 위한 n-피리디닐 아세트아미드 유도체의 경구 제형
WO2014065370A1 (ja) 肺高血圧症治療剤
HK1227306A1 (en) Compositions and methods of treating pulmonary hypertension

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF NAME OF INVENTOR FROM CHRISTOPHER CHRISTOPHER TO DUFTON, CHRISTOPHER